Literature DB >> 10727777

Single and multiple transgenic mice as models for Alzheimer's disease.

F van Leuven1.   

Abstract

Transgenic mice expressing in brain different mutant forms of the Amyloid Precursor Protein, develop functional, cognitive and pathological defects which resemble or are reminiscent of symptoms observed in Alzheimer's disease (AD) patients. The late development of amyloid plaques in aging transgenic APP mice is needed to warrant that the earlier behavioural and cognitive defects are informative for the human disorder. We describe and discuss our work, the rationale behind the approach and the techniques used to generate these APP transgenic mice, including specific experimental problems. The APP transgenic mouse models are being comprehensively characterized and offer excellent perspectives for the study and definition of early biochemical and pathological aspects that are not accessible in human AD patients. The ongoing combination by breeding with other transgenic mouse strains, i.e. mice overexpressing human Presenilin 1, ApoE 4 and protein tau to generate "multiple" transgenic mice, offer additional potential to define the pathological interactions of these genetic factors, known to be involved, directly or indirectly, in dementia of the Alzheimer type. Finally, it must be the aim to obtain transgenic mice that not only model amyloidogenesis, but also the neurofibrillary tangle pathology and the involvement of protein tau.

Entities:  

Mesh:

Year:  2000        PMID: 10727777     DOI: 10.1016/s0301-0082(99)00055-6

Source DB:  PubMed          Journal:  Prog Neurobiol        ISSN: 0301-0082            Impact factor:   11.685


  23 in total

1.  Of mice and men: virtual Hebb-Williams mazes permit comparison of spatial learning across species.

Authors:  D I Shore; L Stanford; W J MacInnes; R M Klein; R E Brown
Journal:  Cogn Affect Behav Neurosci       Date:  2001-03       Impact factor: 3.282

Review 2.  Vaccines for Alzheimer's disease: how close are we?

Authors:  Christopher Janus
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

3.  Role for neuronal insulin resistance in neurodegenerative diseases.

Authors:  Markus Schubert; Dinesh Gautam; David Surjo; Kojihiko Ueki; Stephanie Baudler; Dominic Schubert; Tatsuya Kondo; Jens Alber; Norbert Galldiks; Eckehardt Küstermann; Saskia Arndt; Andreas H Jacobs; Wilhelm Krone; C Ronald Kahn; Jens C Brüning
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-23       Impact factor: 11.205

Review 4.  APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD).

Authors:  R Lalonde; K Fukuchi; C Strazielle
Journal:  Neurosci Biobehav Rev       Date:  2012-02-21       Impact factor: 8.989

5.  Quantitative structure-activity relationship analysis of β-amyloid aggregation inhibitors.

Authors:  Shiri Stempler; Michal Levy-Sakin; Anat Frydman-Marom; Yaniv Amir; Roni Scherzer-Attali; Ludmila Buzhansky; Ehud Gazit; Hanoch Senderowitz
Journal:  J Comput Aided Mol Des       Date:  2010-12-17       Impact factor: 3.686

6.  Dendritic degeneration, neurovascular defects, and inflammation precede neuronal loss in a mouse model for tau-mediated neurodegeneration.

Authors:  Tomasz Jaworski; Benoit Lechat; David Demedts; Lies Gielis; Herman Devijver; Peter Borghgraef; Hans Duimel; Fons Verheyen; Sebastian Kügler; Fred Van Leuven
Journal:  Am J Pathol       Date:  2011-08-10       Impact factor: 4.307

7.  The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity.

Authors:  Gregory Hook; Vivian Hook; Mark Kindy
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

8.  Modeling of tau-mediated synaptic and neuronal degeneration in Alzheimer's disease.

Authors:  Tomasz Jaworski; Sebastian Kügler; Fred Van Leuven
Journal:  Int J Alzheimers Dis       Date:  2010-08-24

9.  Complete phenotypic recovery of an Alzheimer's disease model by a quinone-tryptophan hybrid aggregation inhibitor.

Authors:  Roni Scherzer-Attali; Riccardo Pellarin; Marino Convertino; Anat Frydman-Marom; Nirit Egoz-Matia; Sivan Peled; Michal Levy-Sakin; Deborah E Shalev; Amedeo Caflisch; Ehud Gazit; Daniel Segal
Journal:  PLoS One       Date:  2010-06-14       Impact factor: 3.240

10.  AAV-tau mediates pyramidal neurodegeneration by cell-cycle re-entry without neurofibrillary tangle formation in wild-type mice.

Authors:  Tomasz Jaworski; Ilse Dewachter; Benoit Lechat; Sophie Croes; Annelies Termont; David Demedts; Peter Borghgraef; Herman Devijver; Robert K Filipkowski; Leszek Kaczmarek; Sebastian Kügler; Fred Van Leuven
Journal:  PLoS One       Date:  2009-10-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.